Retatrutide vs Tirzepatide vs Semaglutide: Single, Dual, and Triple Agonists

Incretin-pathway research has moved fast over the past five years, and three molecules define its current trajectory: semaglutide, tirzepatide, and retatrutide. Each represents a distinct generation of receptor engineering — single, dual, and triple agonism — and each has generated a growing body of peer-reviewed trial data on body-weight change in human subjects and mechanistic data from rodent and in vitro models. This article compares the three purely as they appear in the published literature: what receptors they engage, what the trial data show, and why the addition of glucagon-receptor activity in the third generation is scientifically significant. Nothing here is a dosing protocol, and none of it should be read as a claim about any specific product. All compounds referenced are discussed strictly as research use only materials, not for human consumption, and any research materials referenced in connection with SoCal Labs 1776 are intended for laboratory and preclinical research applications only.

Three Generations of Incretin Agonists

The incretin system centers on gut- and pancreas-derived hormones that regulate insulin secretion, appetite, and energy balance: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon itself. Semaglutide, approved by the FDA under specific brand formulations and studied extensively in the STEP trial program, engages only the GLP-1 receptor. Tirzepatide, studied in the SURMOUNT trial program, was engineered as a dual GIP/GLP-1 receptor agonist. Retatrutide, still in clinical development and studied in a published Phase 2 trial, adds a third receptor target — glucagon — making it a GLP-1/GIP/glucagon triple agonist (Jastreboff et al., *NEJM* 2023; PMID 37366315). Researchers frequently describe this progression as "unimolecular polyagonism": a single peptide chain engineered to activate multiple metabolic receptors simultaneously, rather than combining separate drugs.

Semaglutide: The GLP-1 Single Agonist

Semaglutide is a 31-amino-acid GLP-1 receptor agonist with roughly 94% sequence homology to native human GLP-1, modified with a C18 fatty-diacid side chain that promotes albumin binding and extends its half-life to roughly a week, supporting once-weekly dosing regimens in trial protocols. Mechanistically, GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon secretion in a glucose-dependent manner, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake. In the STEP 1 trial (*NEJM*, Wilding et al. 2021), 1,961 adults with obesity or overweight were randomized to semaglutide 2.4 mg weekly (n=1,306) or placebo (n=655), alongside lifestyle intervention, for 68 weeks. The semaglutide group achieved a mean body-weight change of −14.9% versus −2.4% with placebo. A separate 104-week trial in the same program, STEP 5, enrolled its own randomized cohort (not a continuation of the STEP 1 participants) and reported a similar mean reduction of roughly −15.2% at two years versus −2.6% for placebo, suggesting the effect is durable with continued treatment. These are the numbers most frequently cited when researchers describe semaglutide's single-pathway efficacy in human trial populations.

Tirzepatide: The GLP-1/GIP Dual Agonist

Tirzepatide is a single 39-amino-acid peptide, built on a modified GIP backbone with a C20 fatty-diacid moiety for albumin binding, engineered to activate both the GIP receptor and the GLP-1 receptor. Preclinical work suggested that GIP receptor agonism, layered onto GLP-1 activity, could enhance effects on food intake and energy expenditure beyond what GLP-1 agonism achieves alone, although GIP's precise contribution to weight loss in humans is still an active research question. In vitro signaling studies indicate tirzepatide behaves as a near-full agonist at the GIP receptor (closely mimicking native GIP) while showing biased, lower-efficacy signaling at the GLP-1 receptor relative to native GLP-1 — an "imbalanced" receptor-engagement profile researchers have proposed as part of its design rationale (Willard et al., *JCI Insight* 2020). In the SURMOUNT-1 trial (*NEJM*, Jastreboff et al. 2022), 2,539 adults with obesity or overweight without type 2 diabetes were randomized across 5 mg, 10 mg, and 15 mg tirzepatide arms versus placebo for 72 weeks. Reported mean weight reductions (efficacy estimand) were 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg), compared with 2.4% for placebo. The dual-agonist mechanism is generally interpreted in the literature as evidence that adding a second incretin receptor target measurably increases the magnitude of weight change observed in trial populations relative to GLP-1 agonism alone.

Retatrutide: The GLP-1/GIP/Glucagon Triple Agonist

Retatrutide (LY3437943) extends the polyagonist concept a step further by engaging the glucagon receptor in addition to GLP-1 and GIP. This third receptor target is mechanistically distinct: in preclinical models, glucagon receptor signaling in liver and adipose tissue has been linked to increased fatty-acid oxidation and glycogenolysis-driven hepatic energy expenditure, and — via increased sympathetic tone — to browning of white adipose tissue and greater brown-adipose-tissue thermogenic activity, effects proposed to raise energy expenditure independent of appetite suppression. The precise cellular mechanisms, including how much classic uncoupling-protein-1 (UCP1) activity versus other futile-cycling pathways is involved, remain an active area of rodent research. In the published Phase 2 trial (Jastreboff et al., *NEJM* 2023), 338 adults with obesity or overweight were randomized across dose-escalation arms up to 12 mg weekly for 48 weeks. Least-squares mean body-weight change was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg), versus −2.1% for placebo — and the trial reported that weight loss had not yet plateaued by week 48 in the higher-dose groups, suggesting the full effect size may not have been captured within the study period. As with the other two compounds, this data comes exclusively from clinical-stage human trials and is reported here strictly as literature, not as a usage recommendation.

Receptor Coverage Compared

• Semaglutide — GLP-1 receptor only (single agonist).
• Tirzepatide — GLP-1 receptor + GIP receptor (dual agonist).
• Retatrutide — GLP-1 receptor + GIP receptor + glucagon receptor (triple agonist).
• The added glucagon-receptor pathway in retatrutide is the mechanistic differentiator most discussed in the literature: in preclinical models it is associated with increased energy expenditure and lipolysis, proposed to work alongside (not instead of) the appetite-suppressing effects shared by all three compounds.

Reported Weight-Loss Data Side by Side

Reading across the three trial programs, the reported weight-loss magnitudes scale roughly with receptor coverage: approximately 15% for the GLP-1 single agonist (semaglutide, STEP 1, 68 weeks), approximately 22.5% for the GLP-1/GIP dual agonist (tirzepatide, SURMOUNT-1, top dose, 72 weeks), and approximately 24% for the GLP-1/GIP/glucagon triple agonist (retatrutide, Phase 2, top dose, 48 weeks, still trending downward at trial end). These trials differ in duration, dose-escalation schedules, and study populations, so cross-trial comparisons are directional rather than head-to-head — no trial has yet randomized all three molecules against each other in the same protocol. Researchers interpreting this pattern generally attribute the stepwise increase to the additional receptor pathways engaged at each generation, though confirming that causal chain requires more granular mechanistic and head-to-head research.

Comparison Table

• Semaglutide — Receptors: GLP-1 only. Trial: STEP 1 (68 wk). Reported mean weight change: ~14.9–15.2%.
• Tirzepatide — Receptors: GLP-1 + GIP. Trial: SURMOUNT-1 (72 wk, 15 mg). Reported mean weight change: ~22.5%.
• Retatrutide — Receptors: GLP-1 + GIP + glucagon. Trial: Phase 2 (48 wk, 12 mg). Reported mean weight change: ~24.2% (still declining at trial end).

Research Use Only

Everything above is a summary of published, peer-reviewed human trial data and preclinical mechanistic literature — it is not a therapeutic claim, a dosing protocol, or an administration instruction for any person. Semaglutide is FDA-approved under specific brand formulations for specific indications; tirzepatide is FDA-approved under specific brand formulations for specific indications; retatrutide remains investigational and is not approved for any use. Research compounds referenced or sold in connection with this content are intended strictly for in vitro and non-human laboratory research, are not for human consumption, and are not evaluated or approved by the FDA for any therapeutic purpose. This article does not assert that any specific SKU in our catalog is chemically identical to semaglutide, tirzepatide, or retatrutide as studied in the trials cited — researchers sourcing peptides for laboratory work should independently confirm identity and purity. Before using any research material, review the accompanying certificate of analysis, understand our purity standards, and use lot verification to confirm third-party HPLC testing for the specific lot in hand.